GT Biopharma (GTBP) Insider Trading & Ownership $1.06 -0.08 (-7.02%) As of 01:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GT Biopharma (NASDAQ:GTBP) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage3.40%Number OfInsiders Buying(Last 3 Years)2Amount OfInsider Buying(Last 3 Years)$49.98KNumber OfInsiders Selling(Last 3 Years)0 Get GTBP Insider Trade Alerts Want to know when executives and insiders are buying or selling GT Biopharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GTBP Insider Buying and Selling by Quarter GT Biopharma Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails4/11/2023Michael Martin BreenCEOBuy1,666$15.00$24,990.00 4/6/2023Manu OhriCFOBuy1,666$15.00$24,990.00 (Data available from 1/1/2013 forward) GTBP Insider Trading Activity - Frequently Asked Questions Who is on GT Biopharma's Insider Roster? The list of insiders at GT Biopharma includes Manu Ohri, and Michael Martin Breen. Learn more on insiders at GTBP. What percentage of GT Biopharma stock is owned by insiders? 3.40% of GT Biopharma stock is owned by insiders. Learn more on GTBP's insider holdings. GT Biopharma Key ExecutivesMr. Michael Martin Breen (Age 61)Interim CEO & Executive Chairman Compensation: $1.04MMr. Manu Ohri (Age 69)CFO & Secretary Compensation: $647.07kDr. Jeffrey S. Miller M.D.Consulting Chief Scientific Officer, Consulting Chief Medical Officer & Scientific Advisor More Insider Trading Tools from MarketBeat Related Companies ATHA Insider Transactions CLRB Insider Transactions LIXT Insider Transactions IBIO Insider Transactions LEXX Insider Transactions ADAP Insider Transactions BFRG Insider Transactions TXMD Insider Transactions ALVR Insider Transactions FLGC Insider Transactions Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Costco Faces Downgrades, Death Cross, Insider SellingReynolds Consumer Products Stock Price: Insiders Signal a BottomBuy, Sell, or Hold? Insiders Pile Into These 3 Healthcare StocksInsiders Trade Millions in NVIDIA-Linked Navitas, Hims, & Shift45 Stocks Insiders Are Selling That Analysts Say Buy This page (NASDAQ:GTBP) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredChase, Bank of America, Wells Fargo Preparing for BIG ChangeThanks to this brand-new law #S.1582 signed by President Trump… Jeff Brown believes the largest banks in Am...Brownstone Research | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GT Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GT Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access